Novoviah

At Novoviah, we make monitoring for rare antigen-specific T cells easy and sensitive for a clinical trial. Arising from our Founder’s 20+ years’ experience researching and studying celiac disease and inflammatory bowel diseases, Novoviah’s break-through foundation product is the proprietary Novoleukin Test System, a “whole blood antigen-stimulated cytokine release assay” which is substantially more sensitive than conventional fresh PBMC-based ELISpot assay and flow cytometry assays. Novoviah has demonstrated the success of the Novoleukin Test System as a ‘research only product’, firstly in Celiac Disease (Novoleukin-C, clinical validation stage); and is expanding to Type 1 Diabetes, and other medical conditions associated with antigen-specific T cells. Novoviah’s aspiration is to have a Novoleukin Test System available for a wide range of antigens relevant to immune disease, immunotherapies and vaccines, and to explore their clinical utility as diagnostics or monitoring tools. If you are a pharmaceutical or research company developing therapeutics or monitoring tools for indications where specific disease-associated antigen and T cell responses are implicated, contact us to discuss development of a highly sensitive Novoleukin Test System specific to your indication.